Yarrow Bioscience (YARW) announced the completion of its merger with VYNE Therapeutics and previously announced private financings totaling approximately $200 million.
The clinical-stage biotechnology company said it has begun dosing in a Phase 2a/2b trial of YB-101 for Graves’ disease, with or without concurrent thyroid eye disease. Shares of the combined company are expected to begin trading on the Nasdaq Capital Market under the ticker YARW on July 28, 2026.
- YB-101 is a potential first-in-class anti-TSHR monoclonal antibody designed for Graves’ disease and thyroid eye disease.
- The FDA has granted Fast Track Designation for YB-101.
- Phase 2a data from the Graves’ disease trial are expected in the second half of 2027.
- Partner GenSci is evaluating YB-101 in China, with Phase 1 MAD data in thyroid eye disease expected in the second half of 2027.
- Yarrow said its cash balance is expected to support operations into 2028.
- The combined company has approximately 2.8 million common shares outstanding, or approximately 33.6 million on a fully diluted basis.
$VYNE Hedge Fund Activity
We have seen 14 institutional investors add shares of $VYNE stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- LYNX1 CAPITAL MANAGEMENT LP added 1,628,700 shares (+inf%) to their portfolio in Q1 2026, for an estimated $973,148
- NANTAHALA CAPITAL MANAGEMENT, LLC added 1,000,000 shares (+100.0%) to their portfolio in Q1 2026, for an estimated $597,500
- T3 COMPANIES, LLC removed 926,100 shares (-98.0%) from their portfolio in Q2 2026, for an estimated $602,613
- ADAR1 CAPITAL MANAGEMENT, LLC added 810,108 shares (+319.2%) to their portfolio in Q1 2026, for an estimated $484,039
- CITADEL ADVISORS LLC added 483,917 shares (+1585.3%) to their portfolio in Q1 2026, for an estimated $289,140
- ACADIAN ASSET MANAGEMENT LLC removed 256,695 shares (-40.2%) from their portfolio in Q1 2026, for an estimated $153,375
- TWO SIGMA INVESTMENTS, LP added 206,412 shares (+93.8%) to their portfolio in Q1 2026, for an estimated $123,331
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
